002675 Stock Overview
Engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.50 |
| 52 Week High | CN¥19.10 |
| 52 Week Low | CN¥11.33 |
| Beta | 0.40 |
| 11 Month Change | 4.01% |
| 3 Month Change | 11.57% |
| 1 Year Change | -26.07% |
| 33 Year Change | -21.24% |
| 5 Year Change | -16.62% |
| Change since IPO | 126.57% |
Recent News & Updates
Recent updates
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet
Aug 23
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price
Jul 12News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat
May 06Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit
May 05Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?
Mar 15Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark
Feb 27Shareholder Returns
| 002675 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.0% | -4.3% | -3.9% |
| 1Y | -26.1% | -17.7% | 4.0% |
Return vs Industry: 002675 underperformed the CN Biotechs industry which returned -17.7% over the past year.
Return vs Market: 002675 underperformed the CN Market which returned 4% over the past year.
Price Volatility
| 002675 volatility | |
|---|---|
| 002675 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 002675 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002675's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,333 | Zhi Gang Luo | www.dcb-group.com |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for injection, as well as ambroxol hydrochloride dispersible tablets, jinjunling capsule, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind dispelling itch relieving granule. In addition, it offers Technetium [99Tc] Methylene Diphosphonate Injection; Technetium [99mTc] Tc labeled tracers; 2-[18F]FDG that helps to detect the activity of tumor cells; sodium iodide [131I] oral solution; iodine [125I] seed use to treat internal radiation of various malignant tumors; [14C]Urea capsule; and jiabaolin glucosamine chondroitin sulfate capsule.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 002675 fundamental statistics | |
|---|---|
| Market cap | CN¥11.13b |
| Earnings (TTM) | CN¥90.79m |
| Revenue (TTM) | CN¥2.85b |
122.6x
P/E Ratio3.9x
P/S RatioIs 002675 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002675 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.85b |
| Cost of Revenue | CN¥1.65b |
| Gross Profit | CN¥1.21b |
| Other Expenses | CN¥1.12b |
| Earnings | CN¥90.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 42.29% |
| Net Profit Margin | 3.18% |
| Debt/Equity Ratio | 15.4% |
How did 002675 perform over the long term?
See historical performance and comparison